Qiagen has developed liquid biopsy panels for prostate and lung cancer and is set to introduce the products at the American Association for Cancer Research annual meeting this week.
Qiagen, known for its oncology offerings, is set to develop assays for the non-invasive prenatal testing market through a $40 million collaboration with Natera.
SQI Diagnostics and Predictive Health bring cardiovascular diagnostics to the forefront with the launch of a serum-based heart attack probability test.
A $45 million funding round completed by DiaCarta to help develop a liquid biopsy test for colorectal cancer is just the latest proof that venture capitalists continue to see liquid biopsy companies as an attractive investment.
A molecular diagnostics company wants to expand its new cartridge-based platform to help orthopedic surgeons make more informed care decisions for patients with a potential joint infection.
Panelists at the recent J.P. Morgan Healthcare Conference in San Francisco, CA were charged with separating the hype from the reality in the field of diagnostics and offered insight into what products will win in the space.